Johnson & Johnson (NYSE:JNJ) Shares Sold by Taylor Financial Group Inc.

Taylor Financial Group Inc. lessened its stake in Johnson & Johnson (NYSE:JNJ) by 2.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,489 shares of the company’s stock after selling 75 shares during the quarter. Taylor Financial Group Inc.’s holdings in Johnson & Johnson were worth $360,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. IFS Advisors LLC raised its stake in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $35,000. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $32,000. Activest Wealth Management acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $40,000. Finally, NewSquare Capital LLC raised its stake in Johnson & Johnson by 145.8% during the fourth quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock worth $42,000 after acquiring an additional 172 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Trading Up 0.1 %

Shares of NYSE:JNJ opened at $162.94 on Tuesday. The stock has a market capitalization of $392.66 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company has a 50 day moving average price of $155.37 and a 200 day moving average price of $156.26.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $2.29 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Bank of America increased their price objective on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a research note on Wednesday, March 5th. Citigroup dropped their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Leerink Partners dropped their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Raymond James dropped their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Morgan Stanley decreased their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.